Do we need new devices for Intranasal Vaccination?

Drug Development and Delivery

Volumn 11, Issue 3, 2011, Pages 54-59

  Marx, Degenhard ^a   Leitz, Matthias ^b   Fagot, Christophe ^c  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b University of Cooperative Education Stuttgart   (Germany)

^c Engineering Department

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; INFLUENZA VACCINE; NASOVAC; NOSE SPRAY; ULTRAVAC; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY PRODUCTION; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRYOPRESERVATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PACKAGING; DRUG SAFETY; DRUG STORAGE; DRY POWDER; FEAR; HUMAN; IMMUNE RESPONSE; INJECTION; MASS IMMUNIZATION; MEDICAL NEBULIZER; MUCOSAL IMMUNITY; NEEDLE; PATIENT ATTITUDE; PHOBIA; POWDER INHALER; PUMP; SPRAYER; SYRINGE; TRYPANOPHOBIA; VACCINATION; VIRUS LIKE AGENT; WASTE DISPOSAL;

EID: 79954497854     PISSN: 15372898     EISSN: 1944818X     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (3)

1. Aguilar A, et al. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis. 2007;11:394-401.
2. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract. 1995;41(2): 169-175.
3. Kissmann J, et al. Stabilization of measles virus for vaccine formulation. Hum Vaccin. 2008;4(5):350-359.